Cancer Immunology, Immunotherapy

, Volume 60, Issue 9, pp 1221–1225

Therapeutic effects of metformin in breast cancer: involvement of the immune system?

  • Sarah Schott
  • Angelika Bierhaus
  • Florian Schuetz
  • Philipp Beckhove
  • Andreas Schneeweiss
  • Christof Sohn
  • Christoph Domschke
Opinion Paper

DOI: 10.1007/s00262-011-1062-y

Cite this article as:
Schott, S., Bierhaus, A., Schuetz, F. et al. Cancer Immunol Immunother (2011) 60: 1221. doi:10.1007/s00262-011-1062-y

Abstract

Breast cancer and associated diabetes mellitus have gained raising interest as an elevated risk of breast cancer prognosis resulting in increased mortality in diabetic patients. In this context, the long-acting insulin analog glargine and other antidiabetics have been discussed to promote tumorigenesis. In contrast, the biguanide class oral antidiabetic metformin has been shown capable of enhancing cell cycle arrest and inducing apoptosis as well as reducing growth factor signaling. Consequently, several studies are underway to evaluate a possible role of metformin in breast cancer treatment. Although mechanisms involved are not definitely clear yet, here, we discuss metformin’s anticancer effects including the potential impact of the immune system.

Keywords

Metformin Breast cancer Metabolic effects T cell immunity 

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Sarah Schott
    • 1
  • Angelika Bierhaus
    • 2
  • Florian Schuetz
    • 1
  • Philipp Beckhove
    • 3
  • Andreas Schneeweiss
    • 1
  • Christof Sohn
    • 1
  • Christoph Domschke
    • 1
  1. 1.Department of Gynecology and Obstetrics, National Center of Tumor DiseasesUniversity Hospital of HeidelbergHeidelbergGermany
  2. 2.Department of Endocrinology and Clinical ChemistryUniversity Hospital of HeidelbergHeidelbergGermany
  3. 3.Division of Translational Immunology, Tumor Immunology ProgramGerman Cancer Research Center (DKFZ)HeidelbergGermany

Personalised recommendations